​

Emergent BioSolutions (EBS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EBS Stock Forecast

Emergent BioSolutions (EBS) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $51.50, with a high of $65.00 and a low of $38.00. This represents a 392.35% increase from the last price of $10.46.

- $13 $26 $39 $52 $65 High: $65 Avg: $51.5 Low: $38 Last Closed Price: $10.46

EBS Stock Rating

Emergent BioSolutions stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

EBS Price Target Upside V Benchmarks

TypeNameUpside
StockEmergent BioSolutions392.35%
SectorHealthcare Stocks 23.08%
IndustrySpecialty & Generic Drug Manufacturers Stocks27.57%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$10.46$10.46$10.46
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 2511--13
Jan, 2511--13
Dec, 2411--13
Nov, 24231-17
Oct, 24231118
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 04, 2022Wells Fargo$38.00$33.0614.94%263.29%
Apr 29, 2022Chardan Capital$65.00$33.9891.29%521.41%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 30, 2024H.C. WainwrightBuyinitialise
Aug 22, 2024Rodman & RenshawBuyinitialise
Aug 16, 2024Benchmark Co.UnderperformUnderperformhold
Jun 24, 2024Benchmark Co.UnderperformUnderperformhold
Jun 20, 2024BenchmarkBuyBuyhold
Mar 07, 2024BenchmarkPositiveBuyupgrade
Apr 10, 2023BenchmarkHoldPositiveupgrade
Nov 10, 2022BenchmarkHolddowngrade
Apr 29, 2022Chardan CapitalBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-10 $-5 $0 $5 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.79$4.32$-4.47$-14.85-----
Avg Forecast$7.35$5.89$-1.90$-4.84$-1.64$1.29$1.27$1.11$1.31
High Forecast$7.32$5.86$-1.91$-5.05$-1.71$1.23$1.22$1.06$1.25
Low Forecast$7.37$5.91$-1.89$-4.63$-1.57$1.34$1.33$1.16$1.37
Surprise %-21.22%-26.66%135.26%206.82%-----

Revenue Forecast

$1B $1B $1B $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.56B$1.79B$1.12B$1.05B-----
Avg Forecast$1.55B$1.74B$1.09B$1.07B$1.10B$1.11B$1.05B$1.16B$1.22B
High Forecast$1.54B$1.73B$1.08B$1.03B$1.09B$1.07B$1.03B$1.13B$1.18B
Low Forecast$1.55B$1.74B$1.09B$1.10B$1.12B$1.15B$1.07B$1.20B$1.26B
Surprise %0.63%3.12%3.09%-1.65%-----

Net Income Forecast

$-2B $-2B $-1B $-500M $0 $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$305.80M$219.50M$-223.80M$-760.50M-----
Avg Forecast$267.72M$166.73M$-102.72M$-760.50M$-83.80M$65.79M$65.05M$56.83M$67.07M
High Forecast$209.18M$107.76M$-202.07M$-1.64B$-87.44M$62.94M$62.23M$54.36M$64.16M
Low Forecast$326.26M$225.71M$-3.37M$115.75M$-80.16M$68.65M$67.88M$59.30M$69.98M
Surprise %14.22%31.65%117.87%------

EBS Forecast FAQ

Is Emergent BioSolutions stock a buy?

Emergent BioSolutions stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Emergent BioSolutions is a favorable investment for most analysts.

What is Emergent BioSolutions's price target?

Emergent BioSolutions's price target, set by 4 Wall Street analysts, averages $51.5 over the next 12 months. The price target range spans from $38 at the low end to $65 at the high end, suggesting a potential 392.35% change from the previous closing price of $10.46.

How does Emergent BioSolutions stock forecast compare to its benchmarks?

Emergent BioSolutions's stock forecast shows a 392.35% upside, outperforming the average forecast for the healthcare stocks sector (23.08%) and outperforming the specialty & generic drug manufacturers stocks industry (27.57%).

What is the breakdown of analyst ratings for Emergent BioSolutions over the past three months?

  • February 2025: 33.33% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 33.33% Strong Sell.
  • January 2025: 33.33% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 33.33% Strong Sell.
  • December 2024: 33.33% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 33.33% Strong Sell.

What is Emergent BioSolutions’s EPS forecast?

Emergent BioSolutions's average annual EPS forecast for its fiscal year ending in December is $-1.64 for 2024, a -88.96% decrease from the reported $-14.85 in 2023. The prediction for 2025 is $1.29, $1.27 for 2026, $1.11 for 2027, and $1.31 for 2028.

What is Emergent BioSolutions’s revenue forecast?

Emergent BioSolutions's average annual revenue forecast for its fiscal year ending in December is $1.1B for 2024, a 4.68% increase from the reported $1.05B in 2023. The forecast for 2025 is $1.11B, $1.05B for 2026, $1.16B for 2027, and $1.22B for 2028.

What is Emergent BioSolutions’s net income forecast?

For its fiscal year ending in December, Emergent BioSolutions's average annual net income forecast is $-83.798M for 2024, reflecting a -88.98% decrease from the reported $-760M in 2023. The projection for 2025 is $65.79M, $65.05M for 2026, $56.83M for 2027, and $67.07M for 2028.